MaxCyte, Inc.

MXCT ·Healthcare, Diagnostics & Research, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item Jun 2026 Mar 2026 Dec 2025 Sep 2025 Jun 2025 Mar 2025 Dec 2024 Sep 2024
Operating Activities
Net Income $-8.9M $-4.8M $-9.6M $-12.4M $-12.4M $-10.3M $-10.6M $-11.6M
Depreciation & Amortization $953.0K $1.0M $1.1M $1.0M $1.1M $1.1M $1.1M $1.1M
Depreciation $961.0K $1.0M $1.1M $1.1M $1.1M $1.1M — $1.1M
Amortization $17.0K $17.0K $16.0K $15.0K $12.0K $10.0K — —
Stock-Based Compensation $1.2M $1.1M $706.0K $2.0M $3.5M $3.0M $3.1M $3.4M
Net Cash from Operating Activities $-4.7M $-8.2M $-2.7M $-7.5M $-9.9M $-14.4M $-7.8M $-4.4M
Investing Activities
Capital Expenditures $62.0K $72.0K $231.0K $300.0K $584.0K $653.0K $147.0K $406.0K
Business Acquisitions — — $0 $0 $0 $1.8M — —
Net Cash from Investing Activities $6.6M $2.7M $9.7M $5.2M $1.5M $9.5M $-1.7M $3.6M
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $-1.4M $5.0K $105.0K $14.0K $154.0K $383.0K $412.0K $228.0K
Net Change in Cash $485.0K $-5.5M $7.1M $-2.3M $-8.2M $-4.5M $-9.1M $-555.0K
Free Cash Flow $-4.7M $-8.2M $-2.9M $-7.8M $-10.4M $-15.1M $-8.0M $-4.8M
← Newer Page 1 of 3 Older →